Status:
COMPLETED
Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients
Lead Sponsor:
Shimaa M. Abdelgawad
Conditions:
Covid19
COVID-19 Respiratory Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Starting from December 2019, novel coronavirus disease 2019 (COVID-19) pandemic has caused a tremendous economic loss and unprecedented health crisis across the globe. Discovering an effective and saf...
Detailed Description
Objectives: We will evaluate the efficacy of standardized olive leaf capsules as additive therapy to the standard therapeutic regimen (for a period 10 days) on clinical symptoms, viral clearance, imp...
Eligibility Criteria
Inclusion
- Adults.
- Confirmed SARS-CoV-2 diagnosis (positive polymerase chain reaction by nasopharyngeal swab).
- Mild to Moderate COVID-19 patients.
- No history of the current use of olive leaf capsules supplement.
Exclusion
- Severe and critical COVID-19 patients who need hospitalization.
- Patients need ventilatory support or showing chronic obstructive pulmonary disease (COPD).
- Patients showing any chronic disease (except hypertension and diabetes mellitus).
- Patients who have multiorgan failure.
- 3\. Use of alcohol, other investigational medicines, and illegal drugs (during the last 30 days).
Key Trial Info
Start Date :
May 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04873349
Start Date
May 10 2021
End Date
August 1 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shimaa Abdelgawad
Al Fayyum, Egypt, 63514